ReviewAdvances in experimental medicine and biology2025
Pharmacological Maintenance Therapies After Allogeneic Hematopoietic Cell Transplantation.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disease relapse is the leading cause of failure for patients with hematological malignancies who have received allogeneic hematopoietic cell transplantation (HCT). Maintenance therapy administered after HCT is a promising strategy to reduce the incidence of relapse and enhance the curative potential of HCT. Historically, maintenance therapy was not possible due to off-target toxicities from conventional chemotherapy. With the advent of specifically targeted agents-such as those targeting BCR-ABL, FLT3, IDH1, IDH2 and Menin-therapy given in the immediate period after HCT while patients remain in remission has become a reality. Research investigations and clinical applications of this approach have greatly increased in recent years, with a rapidly expanding number of available therapeutic agents waiting to be tested in the post-transplant setting. However, many questions and challenges remain regarding the feasibility and clinical impact of maintenance therapy after HCT. In this chapter, we review the published data as well as ongoing studies regarding the rapidly evolving field of maintenance therapy after HCT.
Indexed as
Identifiers
40488831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.